drugset / Trial / NCT06873334

Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

NCT06873334 ↗

Phase 2/3 Active not recruiting 120 enrolled Skyhawk Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.

Timeline

Start
2025-05-27
Primary completion
2027-05
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator SKY-0515 Small molecule — Oral

Indications